Ethics of AI in vaccine design and in geopolitical negotiation

These two uses have very different risk profiles, so treat them separately, then note the shared principle. (This is the durable ethical analysis; specific 2026 developments such as AI-designed vaccine candidates entering human trials are referenced as instances, not asserted as settled facts.)

AI in vaccine and therapeutic design

The upside is real: models that design antigens or proteins can compress discovery timelines and explore sequence space humans cannot, which matters most for pandemic speed and for neglected diseases.

Core ethical considerations:

• Dual-use and biosecurity. The same generative tools that design a broad-protection vaccine can in principle be steered toward harmful constructs. This demands access controls, screening of synthesis orders, and governance of model weights - the central, non-negotiable concern.
• Validation burden and the "computational gloss". A design being AI-derived says nothing about its safety; it still requires the full chain of preclinical and clinical evidence. The hazard is automation bias - treating a sophisticated in-silico design as if it were already validated. Trial ethics (informed consent, independent oversight, honest reporting of uncertainty) apply unchanged, arguably more strictly.
• Accountability. When a model contributes to a design, responsibility must stay with identifiable humans and institutions; "the model proposed it" cannot dilute liability.
• Equity of access. If AI lowers cost, the ethical default is broad and affordable access - especially for the lower-income-region diseases that often justify the work - not just first-mover commercial capture.
• Transparency and reproducibility. Methods and validation data should be open enough for independent scrutiny, balanced against legitimate biosecurity redaction.

AI in geopolitical negotiation

Here the stakes differ: there is no ground truth to validate against, the setting is adversarial, and errors can escalate.

Core ethical considerations:

• Automation bias in irreversible decisions. Delegating analysis is one thing; letting a model's framing drive choices with war-and-peace consequences risks laundering a guess as authority. A human must own every consequential judgment, with the model's reasoning visible and contestable.
• Manipulability and shared-model risk. If multiple parties (or the same vendor) rely on similar models, an adversary who can probe or poison the model gains leverage, and correlated errors become systemic.
• Opacity versus accountability. Diplomacy is legitimated by responsible human agents; opaque AI recommendations erode the ability to assign responsibility and to explain decisions to publics and institutions.
• Bias and representation. Training data encodes particular state and cultural perspectives; uncritical use can systematically privilege some parties' framings.
• Consent and disclosure. Whether the parties are even told that AI is shaping proposals is itself an ethical question.

The shared principle

In both domains the ethic is the same: AI may augment expert judgment but must not replace accountable human decision-making in high-consequence, low-reversibility settings. Its use must be governed for dual-use risk, validated against real-world evidence where such evidence exists, transparent enough to be contested, and oriented toward equitable rather than narrowly captured benefit.